Kewaunee Scientific (KEQU) Q4 2026 earnings review
Acquisition Tailwinds Fade, Revealing Organic Contraction
Kewaunee Scientific management described fiscal 2026 as an 'excellent year,' highlighting 17.3% annual revenue growth. However, stripping away the inorganic boost reveals a troubling Q4 reality. The Nu Aire acquisition closed exactly one year prior to this quarter (Nov 2024). Consequently, Q4 FY26 was the first clean organic YoY comparison—and revenue contracted 7.5%, while net income fell 30%. The order backlog also deteriorated sharply, shrinking 22% over the last twelve months. The lone bright spot is the balance sheet: management successfully paid off the Nu Aire seller notes early, driving the debt-to-equity ratio down to 0.61x.
🐂 Bull Case
The company reduced long-term debt by roughly $20 million over the year, fully repaying the Seller Notes from the Nu Aire acquisition. Debt-to-equity (net of sale-leaseback) plummeted to a very healthy 0.26x.
The integration of Nu Aire provides Kewaunee with a broader life sciences offering (biosafety cabinets, incubators), diversifying revenue away from purely cyclical laboratory construction.
🐻 Bear Case
Despite management praising a 'resilient' project backlog, actual data shows a severe deceleration. Total backlog dropped from $214.6M at the end of FY25 to $165.9M at the end of FY26.
The laboratory construction portion of the business is suffering from delayed project timelines and tariff-related cost pressures, pushing Q4 LPG segment revenue down 2%.
⚖️ Verdict: 🔴
Bearish. Management's celebratory tone masks the fact that without the inorganic YoY boost of Nu Aire, top-line growth has turned negative. Combined with a rapidly draining backlog and geopolitical delays in the International segment, the near-term operational outlook looks weak despite a pristine balance sheet.
Key Themes
Backlog Contraction Contradicts Positive Narrative
Management noted the 'durability of demand' and a 'resilient' project backlog. The actual numbers tell a completely different story. Order backlog has been bleeding out sequentially all year, falling from $214.6M in 25Q4, to $205.0M in 26Q1, to $192.9M in 26Q2, and finally landing at $165.9M in 26Q4. This represents a 22% YoY collapse, exacerbated by the cancellation of two projects in India. This shrinking pipeline is a massive red flag for FY27 revenue realization.
International Segment Hit by Geopolitics
The International segment reversed from a steady contributor to a significant drag in Q4, with sales plummeting 21.3% YoY to $17.0M. Management explicitly cited logistical complexity and shipment delays in the Middle East tied to the broader regional conflict. Until these logistical bottlenecks clear, this segment's profitability remains vulnerable to timing shifts.
Balance Sheet Transformation
The most definitive win for Kewaunee this year was cash generation and debt reduction. The successful completion of the Seller Note repayment in December 2025 removed a major post-acquisition overhang. Short-term and long-term debt combined dropped from $65.5M to roughly $46.7M. This de-leveraging frees up cash flow to pursue the 'inorganic growth strategy' management hinted at for the future.
Corporate Overhead Continues to Drain EBITDA
The Corporate segment generated an EBITDA loss of $8.5M for the full year (consistent with FY25). Management justifies this as necessary 'strategic investments in people, processes, systems, [and] technology' to scale as a public company. While understandable post-acquisition, investors should monitor when these structural investments will finally yield operating leverage rather than perpetually dragging down consolidated margins.
Construction Volatility & Tariffs
The domestic business, now rebranded as the Lab Products Group (LPG), faced substantial macroeconomic headwinds. Management cited volatility in project delivery timelines, higher input costs, and evolving tariff-related cost pressures. These macro factors directly compressed LPG segment EBITDA from $8.75M in 25Q4 to $6.67M in 26Q4.
Nu Aire Portfolio Expansion
The integration of Nu Aire fundamentally transformed the company's product offering. Moving beyond laboratory casework and fume hoods, Kewaunee now directly supplies biological safety cabinets, laminar airflow workbenches, and CO2 incubators. This broader life-sciences catalog allows for comprehensive, turnkey laboratory solutions, protecting the company from being commoditized in purely structural lab outfitting.
Other KPIs
Decelerating. Down 24% from $8.75 million in the prior year's fourth quarter. While full-year LPG EBITDA was relatively flat ($25.0M vs $25.5M), the Q4 collapse indicates that productivity improvements and cost controls are no longer enough to offset the lower manufacturing volumes in the lab construction business.
Declined from $64.6 million a year ago. This was primarily driven by a strategic drain of cash to extinguish the Nu Aire Seller Notes early. Receivables also tightened from $62.3M to $58.7M, showing improved collections despite the macro volatility.
Guidance
Management provided no quantitative guidance for FY27 in the earnings release. The narrative focuses qualitatively on being 'well positioned' to navigate a 'life sciences market conditions recovery.' Given the 22% contraction in backlog, the absence of forward guidance requires investors to brace for potential near-term revenue weakness.
Key Questions
Backlog Floor
With the backlog contracting 22% year-over-year and two Indian projects cancelled, at what level do you expect the backlog to stabilize, and does the current $165.9M support flat revenue in FY27?
Middle East Logistics
How much revenue is currently trapped in transit or delayed due to the Middle East logistical complexities, and do you expect these shipments to clear in Q1 FY27?
Corporate Expense Leverage
Corporate segment EBITDA losses have stabilized around $8.5 million annually. Are we at the peak of these public company and integration investments, or should we expect this run-rate to continue indefinitely?
Tariff Mitigation
You mentioned tariff-related cost pressures in the LPG segment. Can you quantify the margin impact in Q4 and outline your pricing power to pass these costs onto customers in FY27?